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Volume 60, Number 5 Abstracts 1411reconstruction with custom-made tube grafts constructed from bovine peri-
cardial sheets.
Results: Patients selected for bovine pericardial tube grafting had pre-
viously documented infection that occurred between 1 month and 6 years
after initial prosthesis implantation. One patient had recurrent graft reinfec-
tion, which was attributed to a recurrent aortoduodenal ﬁstula. The patient
eventually underwent a second pericardial tube graft with resolution of the
infection. Follow-up imaging did not reveal any signs of infection in the
other patients. The overall 30-day perioperative mortality rate was 12.5%
(n ¼ 1) and occurred in relation to severe underlying pulmonary disease
and not as a consequence of graft failure.
Conclusions: Pericardial tube grafting is a potential alternative to
conventional surgical methods for the treatment of aortic graft infections
and infected aortic aneurysm. Further investigation of long-term outcomes
is required.
Author Disclosures: B. Radovanovic: Use of device/product: creating
bovine pericardial graft. B. Montreuil: Use of device/product: creating
bovine pericardial graft. M. Chaput: Nothing to disclose. R. Ghali: Use
of device/product: creating bovine pericardial graft.
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Objectives: Surgical dogma holds that chemotherapy increases the
risk of aneurysm growth and rupture. We sought to determine the effect
of cytotoxic chemotherapy on the growth of aortic aneurysms.Methods: All patients undergoing chemotherapy for malignancy with
coexisting aortic aneurysms at our institution between 2000 and 2011 were
identiﬁed. A review of electronic medical records and a re-review of serial
cross-sectional imaging was performed. An additional cohort of patients un-
dergoing aneurysm surveillance during the same period was identiﬁed, and
demographic and anatomic variables were collected. Planned analysis
included descriptive analysis, change in aneurysm diameter over time, and
association of growth or need for intervention with type of chemotherapy
and type of malignancy.
Results: Between 2000 and 2010, there were 125 patients at our
institution with a concurrent diagnosis of aortic aneurysm and malignancy
requiring cytotoxic chemotherapy. Cross-sectional imaging was available
for 91 of the 125 patients. The predominant malignancy type was lung can-
cer in 34 of 91 patients (38%), followed by lymphoma in 21 (23%) and colo-
rectal cancer in 10 (11%). The aneurysms in 53 patients (58%) were
infrarenal. Most patients were treated with more than one class of chemo-
therapeutic agent over 267 days (interquartile range [IQR], 144-
469 days), the majority having at least one cycle of alkylating agents (73
of 91), in addition to antimetabolites (42 of 91) and plant alkyloids/terpe-
noids (40 of 91). Chemotherapy regimens included steroids in 84 patients
(92%). The baseline aneurysm diameter for patients on and not on chemo-
therapeutic agents was 41.4 mm (IQR, 34.9-51.3 mm) and 46.0 mm (IQR,
40-52 mm), respectively. Aneurysm repair during chemotherapy occurred
in eight of 91 patients (9%), but only two required urgent repair due to
aneurysm rupture. The annual rate of aneurysm growth for patients on
and not on chemotherapy was similar (2.3 mm/y vs 2.4 mm/y; P ¼ .69).
Conclusions: In 91 patients over 10 years at our institution, chemo-
therapy did not increase aneurysm growth compared with patients not un-
dergoing treatment for malignancy.
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